



E-News | July 14, 2022 | Vol 12, No 5

## Nursing in the Modern Clinical Trials Era

### Alliance Oncology Nursing Committee



**Lisa A. Kottschade, MSN, APRN, CNP**  
Chair, Alliance Oncology Nursing Committee

"Nursing has often been the cornerstone of the multidisciplinary management of patients undergoing treatment for their cancer, including those involved in clinical trials. This past decade has seen the explosion of new therapies for the treatment of cancer, including immune checkpoint inhibitors, targeted therapy, and cellular therapies. All of these come with unique and very different side effects, including administration, monitoring, and toxicity management." [Read more.](#)

---

**JULY IS NATIONAL  
SARCOMA AND  
BONE CANCER  
AWARENESS MONTH**



---

**Learn more about an active Alliance angiosarcoma trial**

- **A091902: Angiosarcoma**

## Spotlight on Alliance Trials

### Recently Activated Trials

- **A221803 (Reducing Radiation Dermatitis - Breast Cancer)**
- **A091903 (Resected Mucosal Melanoma)**

### Ongoing Trials

- **A011801 (COMPASS HER2 RD/Breast Cancer)**
- **A021602 (CABINET/Advanced Neuroendocrine Tumors)**
- **A021804 (Advanced Pheochromocytoma and Paraganglioma)**
- **A031902 (CASPAR/Metastatic Castration-resistant Prostate Cancer)**
- **A071702 (Somatically Hypermutated Recurrent Glioblastoma)**
- **A081801 (Non-small Cell Lung Cancer)**

## Announcements

- **Call for Nominations: Charles G. Moertel Lecture 2023**
- **2022 Alliance for Clinical Trials in Oncology Foundation Special Projects Allocation Awards**
- **Alliance Myeloma Committee Chair Appointment**
- **Alliance Board of Directors Approve New Program for Procedure-Based Therapy (PPBT)**
- **New Alliance Participant Engagement Portal to Launch Soon**

## Alliance in the News / Cancer Research Briefs

**Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention**

**Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy with Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)**

**Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN $\alpha$   $\pm$  Bevacizumab: Results from CALGB 90206 (Alliance)**

**Biomarker Development: Bedside to Bench**

